Cancer Treatment Centers of America® (CTCA), Phoenix, has earned The Joint Commission’s Gold Seal of Approval® for Lung Cancer Certification by demonstrating continuous compliance and commitment to providing safe and effective patient care. The Gold Seal is a symbol of excellence that reflects the cancer specialty hospital’s commitment within its clinical programs across the continuum of care for lung cancer and outstanding performance in patient care.
“Our Lung Cancer Certification recognizes healthcare organizations committed to fostering continuous quality improvement, patient safety and quality of care,” said Mark Pelletier, RN, MS, chief operating officer, Accreditation and Certification Operations, and chief nursing executive, The Joint Commission. “We commend CTCA Phoenix for being awarded this certification, demonstrating the capability to reduce variation in its clinical processes and to strengthen its program structure and management framework for lung cancer patients.”
CTCA Phoenix underwent a rigorous onsite survey process earlier this year. During the visit, a Joint Commission team evaluated the hospital’s compliance with certification standards developed in consultation with healthcare experts and providers, measurement experts and patients. The reviewers also conducted observations and interviews at the hospital. Throughout the process, CTCA Phoenix demonstrated it meets the highest standards for performance and patient care.
“We’ve put a lot of focus and energies into our Lung Cancer Center, and this disease-specific certification provides credible validation of our high-quality, consistent approach to patient care, treatment and services,” added Kevin Tulipana, DO, FHM, president and CEO, at CTCA Phoenix.”
CTCA Phoenix’s growing Lung Cancer Center has a comprehensive array of diagnostics, treatments and technologies available to identify, diagnose and treat lung cancer. Among the offerings are:
- Lung cancer screening with low-dose CT scans for those at high risk, as recommended by the U.S. Preventive Services Task Force
- Advanced diagnostic technology called Ion by Intuitive, a minimally invasive, robotic-assisted biopsy tool that helps doctors and obtain biopsies from hard-to-reach places in the lung
- Rapid Lung Nodule Diagnosis Program
- Advanced robotic surgery techniques
- Precision medicine drugs and more
For more information about The Joint Commission and The Gold Seal, please visit jointcommission.org.
For more information about the CTCA Phoenix Lung Cancer Center, visit https://www.cancercenter.com/locations/phoenix/ctca-lung-cancer-center.
About Cancer Treatment Centers of America
Cancer Treatment Centers of America (CTCA), part of City of Hope, is a national network of oncology hospitals and outpatient care centers offering an integrated approach that combines surgery, radiation, chemotherapy, immunotherapy and advancements in precision medicine with supportive therapies to manage side effects and enhance quality of life during treatment and into survivorship. CTCA publishes treatment results biannually, including patient experience, length of life, quality of life, patient safety and quality of care. CTCA also offers qualified patients a range of clinical trials that may reveal new treatment options supported by scientific and investigational research. CTCA patient satisfaction scores consistently rank among the highest for all cancer care providers in the country. Visit cancercenter.com for more information.
City of Hope’s mission is to deliver the cures of tomorrow to the people who need them today. Founded in 1913, City of Hope has grown into one the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. As an independent, National Cancer Institute (NCI)-designated comprehensive cancer center, City of Hope reflects a uniquely integrated model spanning cancer care, research and development, academics and training, and innovation initiatives. For more information about City of Hope, follow us on Facebook, Twitter, YouTube, Instagram, or LinkedIn.